Summary & Overview
HCPCS M0235: Monoclonal Antibody Infusion for Hospitalized COVID-19 Patients
HCPCS Level II code M0235 covers the first dose infusion and monitoring of monoclonal antibody products used for post-exposure prophylaxis or treatment of COVID-19 in hospitalized adults and pediatric patients who are on systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation. The code standardizes billing for high-acuity, inpatient-administered monoclonal antibody therapy and clarifies inclusion of monitoring in the first-dose service.
Key payers in this national analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of the clinical context for use, the typical site of service, and the service type tied to this code. The publication outlines which payers cover this service category, common billing modifiers associated with the code, and gaps where data were not provided.
This review also summarizes what providers and administrators need to track for claims processing and documentation related to high-acuity monoclonal antibody infusions in hospitalized COVID-19 patients. The content covers benchmark and policy implications at a national level, including payer variability and areas where additional policy guidance or coding clarification is commonly sought.
Billing Code Overview
HCPCS Level II code M0235 describes an intravenous infusion of monoclonal antibody products with an indication for post-exposure prophylaxis or treatment of COVID-19. The code applies to the first dose and includes both the infusion and required post-administration monitoring, when furnished for hospitalized adult and pediatric patients who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO) only.
Service Type: Intravenous infusion of monoclonal antibody for hospitalized COVID-19 patients receiving systemic corticosteroids and advanced respiratory support
Typical Site of Service: Inpatient hospital setting or other hospital-based locations where patients are admitted and receiving supplemental oxygen, ventilatory support, or ECMO
Clinical & Coding Specifications
Clinical Context
A hospitalized adult with severe COVID-19 pneumonia receiving systemic corticosteroids develops progressive hypoxemic respiratory failure requiring high-flow nasal oxygen. The patient is evaluated by the inpatient infectious disease and critical care teams and meets criteria for monoclonal antibody therapy authorized for treatment/post-exposure prophylaxis in hospitalized patients who are on corticosteroids and require supplemental oxygen or advanced ventilatory support. Orders are placed for intravenous infusion of a monoclonal antibody agent; informed consent is documented; baseline vital signs and relevant laboratory studies (including renal and hepatic function) are reviewed; intravenous access is confirmed and infusion is administered in the inpatient setting (medical ward, step-down unit, or intensive care unit). Continuous monitoring occurs during infusion and for the post-administration observation period; nursing documents infusion start/stop times, medication lot number, lot expiration, and any adverse reactions. Billing uses HCPCS Level II code M0235 for the first dose, with appropriate professional and facility encounter documentation retained in the medical record.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 | No modifier (standard reporting) | Use when no special circumstance modifier applies to the claim. |